Skip to main content

Site notifications

CARBELIN (Nova Pharmaceuticals Australasia Pty Ltd)

Product name
CARBELIN
Date registered
Evaluation commenced
Decision date
Approval time
118 (255 working days)
Active ingredients
Cabergoline
Registration type
New generic medicine
Indication

Inhibition of physiological lactation

CARBELIN is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons.

Treatment of hyperprolactinemic disorders

CARBELIN is indicated for the treatment of pathological hyperprolactinaemia.

Help us improve the Therapeutic Goods Administration site